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There is a growing appreciation by can-
cer researchers of the influence that the 
microenvironment has on tumor growth. 
The late Judah Folkman suggested that 
“the interplay between tumor cells and 
endothelial cells constitutes a highly 
integrated ecosystem.” He proposed 
that because tumors are dependent 
on the formation of new blood ves-
sels (angiogenesis) for growth, target-
ing blood vessels in the surrounding 
tumor microenvironment may prevent 
tumor progression (Folkman, 1972). 
This concept of the tumor “ecosystem” 
has now been extended beyond the 
vasculature to include many diverse 
facets of the microenvironment, such 
as the immune system (van Kempen 
et al., 2003), stromal fibroblasts, and 
the extracellular matrix, including most 
recently the concept of the cancer 
stem cell niche (Sneddon and Werb, 
2007). Underlying this interest in the 
tumor microenvironment is the notion 
that tumor cells under certain condi-
tions cannot grow or survive in the 
absence of support from the microen-
vironment. Indeed, the microenviron-
ment may even drive tumor develop-
ment. Although genetic and epigenetic 
changes may be selected for in cells 
of the microenvironment, their relative 
genomic stability compared to primary 
cancer cells may provide a therapeutic 
target (Kenny et al., 2007) with a lower 
probability of drug resistance devel-
oping. In this issue of Cell, Yang et al. 
(2008) present an elegant use of genet-
ically engineered mouse models to 
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The tumor microenvironment is known to play an important role in tumorigenesis. In this issue, 
Yang et al. (2008) demonstrate that mast cells heterozygous for the Nf1 gene promote the growth 
of neurofibromas in a mouse model of neurofibromatosis and that genetic and pharmacological 
inhibition of these cells is sufficient to block tumor growth.
Figure 1. Alternative Models for the Role of the Stroma in Tumor Development
(Left) Tumor cells acquire genetic and epigenetic changes over time (black arrows) independent of the stroma. To improve survival, tumor cells induce changes 
in the surrounding stroma through the secretion of signals (green arrows). 
(Right) Data from Yang et al. are more consistent with the parallel development of changes in the stroma. Tumor cells and stromal cells both independently undergo 
changes over time (black arrows). Changes in the stroma could facilitate survival of aberrant pre-tumor cells and early tumor cells. These cells can induce further 
changes in the stroma, thus promoting coevolution of stroma and cancer cells over the course of tumorigenesis (green arrows). Aging stroma may be more permissive 
for tumor growth compared with “younger” stroma. In the case of genetic diseases such as neurofibromatosis, the stroma harbors a pre-existing inherited mutation.
dissect the role of inflammation in the 
tumor microenvironment. On the basis 
of their findings, Yang and colleagues 
were able to treat a young patient with 
life-threatening complications of neu-
rofibromatosis type 1 (NF1) in an excit-
ing bench-to-bedside success story.
Previously, these authors dem-
onstrated that formation of benign 
Schwann cell-derived tumors (neuro-
fibromas) requires biallelic loss of the 
Nf1 gene in peripheral nerve Schwann 
cells and loss of one copy of Nf1 in 
the surrounding stroma. Neurofibro-
mas are often infiltrated by mast cells, 
and these authors showed signaling 
between Nf1 mutant Schwann cells 
and Nf1 heterozygous mast cells. In 
their new study, Yang et al. now show in 
vivo that Nf1 heterozygous hematopoi-
etic cells derived from bone marrow 
migrate to developing neurofibromas 
and are required for neurofibroma 
growth. Tumor formation required the 
activity of the c-kit receptor tyrosine 
kinase, which is known to promote 
mast cell migration, proliferation, and 
survival. Taken together with the known 
links between mast cells and neuro-
fibromas, the findings of Yang et al. 
implicate c-kit-dependent mast cells in 
the tumor microenvironment as media-
tors of tumorigenesis. Interestingly, the 
microenvironment in this case is not 
“normal” as wild-type mast cells do 
not support tumor growth. Only Nf1 
heterozygous mast cells with hypersen-
sitivity to migratory stimuli can support 
tumor growth. Other studies have also 
demonstrated that the tumor stroma 
is different from normal stroma. For 
example, the vasculature associated 
with colorectal cancer (St Croix et al., 
2000) and the fibroblasts in basal cell 
carcinoma (Sneddon and Werb, 2007) 
both differ from their normal counter-
parts. However, it is not clear whether 
these changes in the stroma are the 
cause or result of tumor formation.
As cancer research diverges from 
“a reductionist focus” on cancer cell 
mutations (Hanahan and Weinberg, 
2000), there is a growing appreciation 
that intrinsic clonal evolution of the 
cancer cell does not occur in isolation. 
Rather, a variety of local cell popula-
tions can be modulated by environ-
mental and age-related alterations as well as by emerging biological changes 
in associated cancer cells to produce 
the ideal conditions for tumor growth. 
Thus, a model of parallel tumor-pro-
moting changes within an evolving can-
cer organ, rather than the strict clonal 
evolution of the tumor cell suggested 
by earlier models of cancer evolution, 
most accurately represents current 
data (Figure 1). Clearly, in the case of 
the Yang et al. study, causal changes 
in the microenvironment were engi-
neered in the mice and already existed 
in the neurofibromatosis patient (which 
is likely to also be the case for other 
familial disorders). It will be more 
challenging, but of significant impor-
tance, to determine the extent to which 
stromal changes are causal in sporadic 
tumorigenesis.
The concept of cancer as an evolv-
ing organ has implications for devel-
oping therapeutic approaches. Taking 
advantage of the mast cell dependence 
on c-kit activity, Yang and colleagues 
asked whether imatinib mesylate, a 
potent inhibitor of c-kit, could be used 
to treat neurofibromas. Remarkably, not 
only did administration of the compound 
decrease neurofibromas in a mouse 
model of neurofibromatosis, but it was 
also able to shrink a neurofibroma in a 
3-year-old human patient. Subsequent 
clinical trials will determine the robust-
ness and stability of the response to 
imatinib mesylate treatment. Yang et 
al.’s elegant use of genetic engineering 
to block the c-kit receptor specifically 
in stromal cells shows that the state of 
the cancer stroma may be as important 
a factor in therapy development as the 
state of the tumor cells themselves. 
The current use of immunocompro-
mised xenograft mouse models to 
develop cancer therapies has been 
only minimally predictive of therapeu-
tic efficacy in patients. This may be in 
part due to inappropriate microenvi-
ronments for tumor growth, as in the 
case of the widely used subcutaneous 
xenograft mouse model. The weak-
ness of this model system may reflect 
the naive state of the stroma, which 
has not been subjected to the same 
selective pressure as the tumor stroma 
in patients. Greater understanding of 
the tumor microenvironment and its 
relationship to normal stroma will aid Cell 135the development of better tools for 
testing therapeutics and will highlight 
new therapeutic targets. In this regard, 
genetically engineered mouse models 
of human cancers have the advantage 
that cancer cells can coevolve with the 
surrounding stroma, enabling recapitu-
lation of the “highly integrated ecosys-
tem” of the cancer organ.
Human cancer cells tend to be 
genetically unstable and develop new 
genomic aberrations over time. How-
ever, it is less clear whether benign 
tumors such as neurofibromas or 
stromal cells including mast cells share 
this capacity to mutate, as they could 
be subject to greater cell cycle and 
DNA damage control. One of the dif-
ficulties in the use of imatinib mesylate 
for the treatment of cancer has been 
the development of resistance to this 
tyrosine kinase inhibitor through the 
acquisition of mutations in the targeted 
kinases. The hope is that stromal cells 
may be less likely than their associated 
tumor cells to develop drug resistance 
over a patient’s lifetime. The Yang et 
al. study describes a single, albeit 
convincing, case report of success-
ful treatment of a neurofibromatosis 
patient with imatinib mesylate. It will be 
important to see how widely applicable 
this treatment is (particularly in terms 
of neurofibromatosis), whether con-
tinuous drug administration is required 
to suppress the stromal contribution to 
tumorigenesis, and whether drug resis-
tance becomes an issue after long-
term use.
Nearly four decades ago, studies of 
the rare genetic disease retinoblas-
toma led to a new understanding of 
how tumors develop mutations and of 
the role of tumor suppressor genes in 
tumorigenesis (Knudson, 1971). Now, 
studies of the familial disorder neuro-
fibromatosis, such as that of Yang et 
al., are confirming the complexity of 
cellular interactions within tumors and 
demonstrating the vulnerabilities of 
these interactions to therapeutic inter-
vention.
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In Bacillus bacteria, the process of 
sporulation is triggered by nutrient 
starvation, and the resulting spores are 
metabolically dormant and extremely 
resistant to a variety of stress factors 
(Setlow, 2006). As a consequence, 
spores can survive for long periods of 
time, certainly for hundreds of years if 
not more. However, even though these 
spores are dormant, they are continu-
ally monitoring their environment, and 
if conditions favorable for cell growth 
return, the spores can rapidly break 
dormancy and “return to life” (Setlow, 
2003). In the current model for spore 
germination, specific nutrient mole-
cules bind to their cognate germinant 
receptors located in the inner spore 
membrane (Figure 1A). This leads to 
the release of small molecules from 
the spore core, most notably the huge 
depot of dipicolinic acid chelated 1:1 
with divalent cations, largely Ca2+ 
(Ca-DPA), and replacement of these 
small molecules by water. In the dor-
mant spore core, water is maintained 
at an extremely low level, likely to pre-
vent enzymatic activity. The release of 
Ca-DPA activates enzymes that can 
degrade the spore’s peptidoglycan cor-
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core. Hydrolysis of the cortex leads to 
the swelling of the spore core and fur-
ther water uptake (Figure 1B). The water 
content is then high enough to allow 
enzyme action, metabolism, and mac-
romolecular synthesis, with vegetative 
growth following soon thereafter.
In this issue, Shah et al. (2008) report 
evidence for an alternative and very 
different mechanism for initiating ger-
mination, based largely on work with 
the model organism and spore former 
Bacillus subtilis, a species of Gram-
positive bacteria. They find that germi-
nation of B. subtilis spores, as well as 
those of several other Bacillus species, 
can be triggered by extremely low con-
centrations (≤1 pg/ml) of muropeptides, 
which are produced by degradation of 
the peptidoglycan that comprises the 
cell wall of most bacteria. Such degra-
dation is a normal feature of bacterial 
cell growth. In growing Gram-negative 
bacteria, muropeptides are not gen-
erally released in significant amounts 
due in large part to efficient recycling, 
whereas Gram-positive bacteria recy-
cle muropeptides poorly (Doyle et al., 
1988; Mauck et al., 1971). As a conse-
quence, high levels of muropeptides in 
the environment could indicate abun-
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(2008). Cell, this issue.dant growth of Gram-positive bacteria 
and thus provide a logical environmen-
tal signal that could initiate spore ger-
mination. The muropeptide signal lead-
ing to B. subtilis spore germination is 
not just from any muropeptide but only 
from those that have the amino acid 
meso-diaminopimelate (Dpm) at posi-
tion three of the stem peptide linked 
to the muropeptide’s oligosaccharide 
backbone. Dpm is the amino acid 
found in this position in peptidoglycan 
of growing B. subtilis cells. In con-
trast, the peptidoglycan from at least 
one other Bacillus species, B. spha-
ericus, and other Gram-positive bac-
teria such as Staphylococcus aureus 
contain L-lysine in the third position of 
the stem peptide (Hungerer and Tipper, 
1969; Schleifer and Kandler, 1972), and 
muropeptides from this type of pepti-
doglycan are ineffective at eliciting B. 
subtilis spore germination.
Notably, the triggering of spore ger-
mination by the appropriate muropep-
tides occurs in the absence of all nutri-
ent germinant receptors, suggesting 
that muropeptides do not trigger ger-
mination through the nutrient germinant 
receptors. As a consequence, Shah et 
al. (2008) sought to identify bacterial 
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